Article
Osimertinib-induced DNA resistance mutations in cerebrospinal fluid of epidermal growth factor receptor-mutated non-small-cell lung carcinoma patients developing leptomeningeal metastases: Osimertinib Resistance Analysis-leptomeningeal metastases study.
Neuro-oncology - 5 Dec 2024
van der Wel J W Tijmen, Boelens Mirjam C, Jebbink Merel, Smulders Sietske A, Maas Klaartje W, Luitse Merel J A, Compter Annette, Boltjes Robin P B, Sol Nik, Monkhorst Kim, van den Broek Daan, Smit Egbert F, de Langen Adrianus J, Brandsma Dieta
Abstract excerpt
BACKGROUND: Diagnosis and treatment of leptomeningeal metastases (LM) in epidermal growth factor receptor mutation-positive (EGFRm +) non-small-cell lung carcinoma (NSCLC) is challenging. We aimed to identify resistance mechanisms (RM) to osimertinib in cerebrospinal fluid (CSF) and plasma. METHODS: EGFRm + patients with new or progressive LM during osimertinib were enrolled. NGS Ampliseq was performed on DNA...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.